Abstract

A 40-year-old white male was found dead in bed in a group home for mentally ill adults. The decedent had been diagnosed a paranoid schizophrenic. An autopsy was performed at the Office of the Cuyahoga County Coroner in Cleveland, Ohio. Toxicological testing detected olanzapine and citalopram in post mortem specimens. Multiple fluids and tissues were assayed by liquid-liquid extraction followed by gas chromatography with nitrogen phosphorus detection, and qualitative confirmation by electron impact gas chromatography/mass spectrometry. Drug concentrations [olanzapine : citalopram; mg/L or mg/Kg] determined in this case are the highest reported to date involving these drugs- 1.38:3.35 heart blood, 1.11:1.65 femoral blood, 60.24:32.43 urine, 6.47:10:71 liver, and 38.36:49.16 lung, respectively. Drug concentrations in tissues were found to be the highest in lung for both drugs and lowest in the heart. Citalopram but not olanzapine was detected in bone. The cause of death was ruled acute intoxication by the combined effects of olanzapine and citalopram and the manner, accident.

References

1.
Flanagan
R J
.
Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors
.
Ann Clin Biochem
 0004-5632
1998
;
35
:
261
7
.
2.
Jenkins
A J
,
Gubanich
K
.
Disposition of citalopram in biological specimens from postmortem cases
.
J Forensic Sci
 0022-1198
2002
;
47
(
1
):
159
64
.
3.
Jenkins
A J
,
Sarconi
K M
,
Raaf
H N
.
Determination of olanzapine in a postmortem case
.
J Anal Toxicol
 0146-4760
1998
;(
22
):
605
9
.
4.
Merrick
T C
,
Felo
J A
,
Jenkins
A J
.
Tissue distribution of olanzapine in a postmortem case
.
Amer J Forensic Med Pathol
 0195-7910
2001
;
22
(
3
):
270
4
.
5.
Anderson
D T
,
Kuwahara
T
.
Thirty-five case studies involving postmortem tissue distributions of olanzapine (Zyprexa)
. In:
Spiehler
V
, editor.
Proceedings of the SOFT/TIAFT Joint Meeting
; 1998 Oct 5–9;
Albuquerque (NM)
.
6.
Levine
B S
,
Wu
S C
,
Smialek
J E
.
Olanzapine concentrations in forensic investigations
. In:
Spiehler
V
, editor.
Proceedings of the SOFT/TIAFT Joint Meeting
; 1998 Oct 5–9;
Albuquerque (NM)
.
7.
Fulton
B
,
Goa
K
.
Olanzapine A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
.
Drugs
 0012-6667 1997 February
53
;(
2
):
281
98
.
8.
Olesen
O V
,
Linnet
K
.
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication
.
Ther Drug Monit
 0163-4356
1999
;
21
:
87
90
.
9.
Physicians' Desk Reference
. 58th ed.
Montvale, NJ
:
Thomson PDR
,
2004
.
10.
Weigmann
H
,
Gerek
S
,
Zeisig
A
,
Muller
M
,
Hartter
S
,
Hiemke
C
.
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutuc drug monitoring service
.
Ther Drug Monit
 0163-4356
2001
;(
23
):
410
3
.
11.
Shimada
T
,
Yamazaki
H
,
Mimura
M
,
Inui
Y
,
Guengerich
F P
.
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
.
J Pharmacol Exp Ther
 0022-3565
1994
;
270
:
414
23
.
12.
Rasmussen
B B
,
Brosen
K
.
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
Ther Drug Monit
 0163-4356
2000
;
22
:
143
54
.
13.
Baumann
P
.
Pharmacology and pharmacokinetics of citalopram and other SSRIs
.
Int Clin Psychopharmacol
 0268-1315
1996
;
11
Suppl1
:
5
11
.
14.
Dams
R
,
Benijts
TH P
,
Lambert
W E
,
Van Bocxlaer
J F
,
Van Varenbergh
D
,
Van Peteghem
C
, et al
.
A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication
.
J Anal Toxicol
 0146-4760
2001
;
25
;
147
51
.
This content is only available via PDF.
You do not currently have access to this content.